

BIOCON GROUP

FACT SHEET

September - 2018

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET
(Rs Cr)

	September 30, 2018	March 31, 2018
ASSETS		
Non-current assets		
(a) Property, plant and equipment	4,145	3,630
(b) Capital work-in-progress	847	779
(c) Goodwill	26	26
(d) Other intangible assets	65	43
(e) Intangible assets under development	635	524
(f) Investments in associates and a joint venture	63	64
(g) Financial assets	-	-
Investments	412	-
Derivative assets	61	111
Other financial assets	28	25
(h) Income tax asset, net	135	127
(i) Deferred tax asset, net	384	193
(j) Other non-current assets	326	319
	7,127	5,841
Current assets		
(a) Inventories	878	723
(b) Financial assets		
Investments	470	611
Trade receivables	1,039	1,064
Cash and cash equivalents	576	501
Other bank balances	660	822
Derivative assets	57	99
Other financial assets	481	192
(c) Other current assets	156	137
	4,317	4,149
TOTAL	11,444	9,990
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	300	300
(b) Other equity	5,404	4,881
Equity attributable to owners of the Company	5,704	5,181
Non-controlling interests	486	468
	6,190	5,649
Non-current liabilities		
(a) Financial liabilities		
Borrowings	1,846	1,790
Derivative liability	180	18
Other financial liabilities	-	-
(b) Provisions	53	49
(c) Other non-current liabilities	633	342
	2,712	2,199
Current liabilities		
(a) Financial liabilities		
Borrowings	270	130
Trade payables	1,073	1,006
Derivative liability	67	6
Other financial liabilities	675	556
(b) Provisions	60	47
(c) Income tax liability, net	195	89
(d) Other current liabilities	202	308
	2,542	2,142
TOTAL	11,444	9,990

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	H1 FY 2019	H1 FY 2018	Variance
<u>INCOME</u>			
Small molecules	832	713	17%
Biologics	617	340	82%
Branded formulations	311	306	2%
Research services	825	626	32%
Inter-segment	(140)	(83)	68%
Revenue from operations #	2,445	1,902	29%
Other income	123	105	18%
TOTAL REVENUE	2,568	2,007	28%
<u>EXPENDITURE</u>			
Material & Power costs	997	833	20%
Staff costs	500	397	26%
Research & Development expenses*	121	112	8%
Other expenses	249	186	34%
Manufacturing, staff & other expenses	1,867	1,528	22%
EBITDA	701	479	46%
Interest & Finance charges	37	30	22%
Depreciation & Amortisation	211	192	10%
Share of profit in JV / Associate, net	-	(10)	-104%
PBT BEFORE EXCEPTIONAL ITEM	453	267	70%
Exceptional item, Net	189	-	-
PBT	642	267	140%
Taxes	107	80	34%
Taxes on exceptional item	18	-	-
NET PROFIT BEFORE MINORITY INTEREST	517	187	176%
Minority interest	42	37	13%
NET PROFIT FOR THE PERIOD	475	150	217%
EPS Rs.	7.9	2.5	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	11	9	
* Gross Research & Development expenses	208	189	

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	Q2 FY 19	Q2 FY 18	Variance
INCOME			
Small molecules	432	351	23%
Biologics	367	156	136%
Branded formulations	164	176	-7%
Research services	419	335	25%
Inter-segment	(61)	(49)	25%
Revenue from operations #	1,321	969	36%
Other income	54	50	7%
TOTAL REVENUE	1,375	1,019	35%
EXPENDITURE			
Material & Power costs	506	423	20%
Staff costs	263	204	29%
Research & Development expenses*	77	54	43%
Other expenses	135	105	28%
Manufacturing, staff & other expenses	981	786	25%
EBITDA	394	233	69%
Interest & Finance charges	19	14	36%
Depreciation & Amortisation	112	93	20%
Share of profit in JV / Associate, net	1	(6)	-115%
PBT BEFORE EXCEPTIONAL ITEM	262	132	99%
Exceptional item, Net	189	-	-
PBT	451	132	243%
Taxes	55	43	30%
Taxes on exceptional item	18	-	-
NET PROFIT BEFORE MINORITY INTEREST	378	89	324%
Minority interest	23	20	13%
NET PROFIT FOR THE PERIOD	355	69	416%
EPS Rs.	5.9	1.1	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	5	8	
* Gross Research & Development expenses	120	96	

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	Q2 FY 19	Q1 FY 19	Variance
INCOME			
Small molecules	432	400	8%
Biologics	367	250	47%
Branded formulations	164	147	11%
Research services	419	406	3%
Inter-segment	(61)	(79)	-23%
Revenue from operations #	1,321	1,124	18%
Other income	54	69	-21%
TOTAL REVENUE	1,375	1,193	15%
EXPENDITURE			
Material & Power costs	506	491	3%
Staff costs	263	237	11%
Research & Development expenses*	77	44	74%
Other expenses	135	114	18%
Manufacturing, staff & other expenses	981	886	11%
EBITDA	394	307	28%
Interest & Finance charges	19	18	7%
Depreciation & Amortisation	112	99	13%
Share of profit in JV / Associate, net	1	(1)	-280%
PBT BEFORE EXCEPTIONAL ITEM	262	191	37%
Exceptional item, Net	189	-	-
PBT	451	191	136%
Taxes	55	52	6%
Taxes on exceptional item	18	-	0%
NET PROFIT BEFORE MINORITY INTEREST	378	139	172%
Minority interest	23	19	24%
NET PROFIT FOR THE PERIOD	355	120	196%
EPS Rs.	5.9	2.0	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	5	5	
* Gross Research & Development expenses	120	88	